These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 32023529)

  • 1. An Empirical Analysis of Noninferiority Studies in Oncology: Are They Good Enough?
    Haslam A; Gill J; Prasad V
    J Natl Compr Canc Netw; 2020 Feb; 18(2):161-167. PubMed ID: 32023529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methodological quality of oncology noninferiority clinical trials.
    Wayant C; Ross A; Vassar M
    Crit Rev Oncol Hematol; 2020 May; 149():102938. PubMed ID: 32172223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing the Justification, Funding, Success, and Survival Outcomes of Randomized Noninferiority Trials of Cancer Drugs: A Systematic Review and Pooled Analysis.
    Gyawali B; Tessema FA; Jung EH; Kesselheim AS
    JAMA Netw Open; 2019 Aug; 2(8):e199570. PubMed ID: 31469391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current Issues in Conduct and Reporting of Noninferiority Randomized Controlled Trials in Surgical Management of Cancer Patients.
    Parsyan A; Marini W; Fazelzad R; Moher D; McCready D
    Ann Surg Oncol; 2021 Jan; 28(1):39-47. PubMed ID: 32430749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statistical issues and recommendations for noninferiority trials in oncology: a systematic review.
    Tanaka S; Kinjo Y; Kataoka Y; Yoshimura K; Teramukai S
    Clin Cancer Res; 2012 Apr; 18(7):1837-47. PubMed ID: 22317762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality of reporting of noninferiority and equivalence randomized trials.
    Le Henanff A; Giraudeau B; Baron G; Ravaud P
    JAMA; 2006 Mar; 295(10):1147-51. PubMed ID: 16522835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Empirical Consequences of Current Recommendations for the Design and Interpretation of Noninferiority Trials.
    Aberegg SK; Hersh AM; Samore MH
    J Gen Intern Med; 2018 Jan; 33(1):88-96. PubMed ID: 28875400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A systematic review of noninferiority margins in oncology clinical trials.
    Hashim M; Vincken T; Kroi F; Gebregergish S; Spencer M; Wang J; Kampfenkel T; Lam A; He J
    J Comp Eff Res; 2021 Apr; 10(6):443-455. PubMed ID: 33728935
    [No Abstract]   [Full Text] [Related]  

  • 9. Noninferiority Designed Cardiovascular Trials in Highest-Impact Journals.
    Bikdeli B; Welsh JW; Akram Y; Punnanithinont N; Lee I; Desai NR; Kaul S; Stone GW; Ross JS; Krumholz HM
    Circulation; 2019 Jul; 140(5):379-389. PubMed ID: 31177811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Room for improvement in conducting and reporting non-inferiority randomized controlled trials on drugs: a systematic review.
    Wangge G; Klungel OH; Roes KC; de Boer A; Hoes AW; Knol MJ
    PLoS One; 2010 Oct; 5(10):e13550. PubMed ID: 21048948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Need for Combined Assessment of Multiple Outcomes in Noninferiority Trials in Oncology.
    Jatoi I; Gail MH
    JAMA Oncol; 2020 Mar; 6(3):420-424. PubMed ID: 31830235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic qualitative review of randomised trials conducted in nonsmall cell lung cancer with a noninferiority or equivalence design.
    Paesmans M; Grigoriu B; Ocak S; Roelandts M; Lafitte JJ; Holbrechts S; Berghmans T; Meert AP; Moretti L; Danyi S; Pasleau F; Ameye L; Van Meerhaeghe A; Sculier JP
    Eur Respir J; 2015 Feb; 45(2):511-24. PubMed ID: 25537559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deficient reporting and interpretation of non-inferiority randomized clinical trials in HIV patients: a systematic review.
    Hernandez AV; Pasupuleti V; Deshpande A; Thota P; Collins JA; Vidal JE
    PLoS One; 2013; 8(5):e63272. PubMed ID: 23658818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-analysis of noninferiority and equivalence trials: ignoring trial design leads to differing and possibly misleading conclusions.
    Acuna SA; Dossa F; Baxter N
    J Clin Epidemiol; 2020 Nov; 127():134-141. PubMed ID: 32540386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reporting of noninferiority and equivalence randomized trials for major prostaglandins: a systematic survey of the ophthalmology literature.
    Eyawo O; Lee CW; Rachlis B; Mills EJ
    Trials; 2008 Dec; 9():69. PubMed ID: 19055743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Most noninferiority trials were not designed to preserve active comparator treatment effects.
    Tsui M; Rehal S; Jairath V; Kahan BC
    J Clin Epidemiol; 2019 Jun; 110():82-89. PubMed ID: 30858020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-Inferiority Trials: A Systematic Review on Methodological Quality and Reporting Standards.
    Sengul A; Escobar E; Flores JR; Kwok M; Kono S; Guyatt G; Jackevicius CA
    J Gen Intern Med; 2024 Jul; ():. PubMed ID: 38954320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do oncology researchers adhere to reproducible and transparent principles? A cross-sectional survey of published oncology literature.
    Walters C; Harter ZJ; Wayant C; Vo N; Warren M; Chronister J; Tritz D; Vassar M
    BMJ Open; 2019 Dec; 9(12):e033962. PubMed ID: 31892667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adherence to reporting guidelines and clinical trial registration policies in oncology journals: a cross-sectional review.
    Wayant C; Moore G; Hoelscher M; Cook C; Vassar M
    BMJ Evid Based Med; 2018 Jun; 23(3):104-110. PubMed ID: 29653939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Noninferiority Trial Design: Opportunities and Challenges.
    Adidharma W; Nguyen SN; Waljee JF
    J Hand Surg Am; 2022 Nov; 47(11):1101-1106. PubMed ID: 36182582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.